MedPage Today on MSN
First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma
The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...
The Well News on MSN
FDA approves add-on treatment for severe asthma
WASHINGTON - The Food and Drug Administration has approved Exdensur as an add-on maintenance treatment for patients aged 12 ...
Pharmaceutical Technology on MSN
GSK obtains FDA approval for Exdensur in severe asthma
Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.
The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.
The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...
Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...
The FDA has approved Exdensur depemokimab-ulaa as an add-on maintenance therapy for severe asthma in patients aged 12 and older, supported by Phase III SWIFT trial data showing significant reductions ...
With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...
In today’s ACT Brief, we look at emerging operational changes aimed at reducing site burden, review the FDA approval of GSK’s ...
The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.
In the 12 months after starting tezepelumab, patients with severe asthma had fewer exacerbations, a lower cumulative oral ...
A 6-year-old boy died after he suffered a 'severe asthma attack' during a shopping trip with his mom. Magnus Landon Kayde ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback